EVO

Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.

Wall Street analysts forecast EVO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EVO is 6.00 USD with a low forecast of 5.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Evotec SE revenue for the last quarter amounts to 191.55M USD, decreased -5.70 % YoY.

Evotec SE. EPS for the last quarter amounts to -0.28 USD, increased 12.00 % YoY.

Evotec SE (EVO) has 4827 emplpoyees as of January 10 2026.

Today EVO has the market capitalization of 1.30B USD.